Pozzolengo, Italy

Dieter Wolfgang Hamprecht

This inventor holds 36 USPTO granted patents and 11 published patent applications, primarily in Glucagon Analogues. Top assignees: Boehringer Ingelheim International Gmbh, Zealand Pharma A/s. Active years: 2014-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dieter Wolfgang Hamprecht. Retrieved from https://idiyas.com/inventor/dieter-wolfgang-hamprecht

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 36 

% Patents Active = 97.2

Average Co-Inventor Count = 4.2

ph-index = 7

Forward Citations = 140(Granted Patents)


Location History:

  • Ingelheim am Rhein, DE (2015)
  • North Curl Curl, AU (2019)
  • Pozzolengo, IT (2014 - 2024)

Company Filing History:


Years Active: 2014-2025

Loading Chart...
Areas of Expertise:
Glucagon Analogues
Amylin Analogues
Heteroarylcarboxamide Derivatives
Benzimidazolium Compounds
Pyrazine Amide Compounds
Tertiary Amines
Bicyclic Ring System
Indanyloxyphenyl
Annelated Phenoxyacetamides
Substituted Pyrazines
Tricyclic Pyridine Derivatives
36 patents (USPTO):Explore Patents

Title: Dieter Wolfgang Hamprecht: A Visionary Inventor Shaping the Future of Healthcare Innovations

Introduction: Dieter Wolfgang Hamprecht, a distinguished inventor based in Pozzolengo, Italy, is renowned for his remarkable passion for innovation and relentless pursuit of excellence in the field of inventions. With 34 patents to his name, Hamprecht has solidified his position as a true pioneer, inspiring the next generation of inventors to dream big and push the limits of what is possible.

Latest Patents: Among his latest inventions, Hamprecht has revolutionized the field of healthcare with his groundbreaking patents on Acylated Glucagon Analogues and Amylin Analogues. The former provides innovative materials and methods for treating obesity, excess weight, diabetes, and other metabolic disorders, offering novel acylated glucagon analogue peptides with increased selectivity for the GLP-1 receptor. The latter patent introduces stable and long-acting amylin analogues for the treatment and prevention of various diseases, including obesity and diabetes, in liquid formulation.

Career Highlights: Throughout his illustrious career, Hamprecht has made significant contributions to leading pharmaceutical companies, including Boehringer Ingelheim International GmbH and Zealand Pharma A/S. His expertise and dedication to innovation have played a pivotal role in advancing healthcare solutions and improving patients' quality of life.

Collaborations: Hamprecht's collaborative spirit is evident in his partnership with esteemed colleagues such as Jakob Lind Tolborg and Ditte Riber. Together, they have worked tirelessly to bring cutting-edge inventions to fruition, fostering a culture of creativity and teamwork in the field of medical research.

Conclusion: Dieter Wolfgang Hamprecht's unwavering commitment to innovation and his visionary approach to invention have undoubtedly left an indelible mark on the world of healthcare. His pioneering patents and collaborative endeavors serve as a testament to his extraordinary talent and dedication, inspiring others to push the boundaries of what is possible in the pursuit of creating a healthier and more sustainable future.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…